<DOC>
	<DOC>NCT01403064</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of ALD518 in modifying the course of oral mucositis in subjects with head and neck cancer receiving concomitant chemotherapy and radiotherapy</brief_summary>
	<brief_title>Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects</brief_title>
	<detailed_description />
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<criteria>Have recently diagnosed (&lt; than 6 months prior to screening visit date), pathologically confirmed, nonmetastatic SCC of the oral cavity, oropharynx, hypopharynx or larynx that will be treated with CRT as firstline treatment; subjects with a history of surgical management (approximately 46 weeks before RT with sufficient time for postsurgical healing) are eligible Have a plan to receive a continuous course of conventional external beam irradiation delivered by intensitymodulated radiotherapy (IMRT) as single daily fractions of 2.0 to 2.2 Gy, with a cumulative radiation dose between 55 and 72 Gy. Have a plan to receive a standard cisplatin CT regimen administered triweekly (80 to 100 mg/m2, on Days 0, 21, and 42) or weekly (30 to 40 mg/m2) or a standard carboplatin regimen administered weekly (100 mg/m2) Have an Eastern Cooperative Oncology Group (ECOG) performance status â‰¤ 1 CRP &lt; 80 mg/L Have adequate hematopoietic, hepatic, and renal function at the screening visit Tumor of the lips, sinuses, salivary glands, nasopharynx or unknown primary tumor Metastatic disease (M1) Stage IV C Any prior history of head and neck cancer Prior radiation to the head and neck Have had a major surgical procedure, other than for HNC, or significant traumatic injury within 4 weeks prior to the initiation of RT; or anticipation of need for a major surgical procedure during the clinical trial Active infectious disease, excluding oral candidiasis Have OM at the screening visit Have a history of hypersensitivity to monoclonal antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Oral mucositis; head and neck cancer; chemotherapy; radiotherapy</keyword>
</DOC>